BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdelaziz AO, Nabil MM, Abdelmaksoud AH, Shousha HI, Hashem MB, Hassan EM, Salah A, Omran DA, Elbaz TM. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. Eur J Gastroenterol Hepatol 2019;31:75-9. [PMID: 30199473 DOI: 10.1097/MEG.0000000000001264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Fatima T, Mumtaz H, Khan MH, Rasool S, Tayyeb M, Haider MZ, Hussain ST, Shahzad A, Ali S, Hussain T. Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy. Cureus 2020;12:e11565. [PMID: 33364092 DOI: 10.7759/cureus.11565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752 [PMID: 34904042 DOI: 10.4254/wjh.v13.i11.1743] [Reference Citation Analysis]
3 Pascut D, Cavalletto L, Pratama MY, Bresolin S, Trentin L, Basso G, Bedogni G, Tiribelli C, Chemello L. Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. Cancers (Basel) 2019;11:E1773. [PMID: 31717959 DOI: 10.3390/cancers11111773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
4 Khalid J, Umar M, Ur-Rehman T, Ali M, Khan GM. Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. Infect Agent Cancer 2020;15:35. [PMID: 32508980 DOI: 10.1186/s13027-020-00300-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Joko K, Mashiba T, Ochi H, Yano R, Sato K, Okujima Y, Aono M, Azemoto N, Takechi S, Yokota T, Jinoka R, Moriyama Y, Nishiyama M. Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection. Euroasian J Hepatogastroenterol 2019;9:78-83. [PMID: 32117695 DOI: 10.5005/jp-journals-10018-1305] [Reference Citation Analysis]
6 El Fayoumie M, Abdelhady M, Gawish A, Hantour U, Abdelkhaleek I, Abdelraheem M, Alsawak A, Alwassief A, Elbahrawy A. Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. Gastrointest Tumors 2020;7:50-60. [PMID: 32399465 DOI: 10.1159/000505326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Muzica CM, Stanciu C, Cijevschi-prelipcean C, Girleanu I, Huiban L, Petrea OC, Singeap A, Cojocariu C, Cuciureanu T, Sfarti C, Zenovia S, Chriac S, Stefanescu G, Ciortescu I, Lupașcu-ursulescu C, Miftode E, Trifan A. Long-term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.115910] [Reference Citation Analysis]
8 Ismail MS, Mohamed I, Polychronopoulou E, Goss JA, Kuo YF, Kanwal F, Jalal PK. Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:701-11. [PMID: 34235107 DOI: 10.2147/JHC.S309354] [Reference Citation Analysis]